In recent years, there has been increasing use of BRAF-inhibiting drugs for the treatment of various malignancies, including melanoma. However, these agents are associated with the development of other nonmelanoma skin lesions, in particular squamoproliferative lesions such as keratoacanthomas (KAs), squamous cell carcinomas, and BRAF inhibitor-associated verrucous keratoses. The molecular pathogenesis of these lesions is of interest, not only for therapeutic reasons, but also for the insight it might provide into the development of similar lesions in a sporadic setting. We used next-generation sequencing to compare the mutational profiles of lesions after treatment with a BRAF inhibitor, with similar lesions arising sporadically. HRAS mutations were common among the BRAF inhibitor-induced lesions, being identified in 56%, compared with 14% of lesions in the sporadic group (P = 0.002). Thus, despite similar histomorphological appearances, the underlying molecular mechanisms may be different. In addition, within the BRAF inhibitor-associated group, the lesions designated as KAs and BRAF inhibitor-associated verrucous keratoses had a similar mutational profile (mutations in PIK3CA, APC, and HRAS), which was distinct to that seen in squamous cell carcinomas (FGFR3, CDKN2A, and STK11). We have previously noted histological overlap between KAs and BRAF inhibitor-associated verrucous keratoses, and this finding supports the notion that they may represent morphological or temporal variants of a single lesion type.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmoldx.2015.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study.
Am J Ophthalmol
November 2024
From the Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine (H.J., C.S.L., S.H.B., S.S.K., Y.J.K.), Seoul, Republic of Korea. Electronic address:
Article Synopsis
- The study investigates the incidence of noninfectious uveitis among skin melanoma and lung cancer patients receiving different treatments: BRAF inhibitors, immune checkpoint inhibitors (ICIs), or conventional chemotherapy.
- An analysis of over 77,000 patients showed that those on BRAF inhibitors had a significantly higher risk of uveitis (2.27%) compared to those on ICIs (0.35%) or chemotherapy (0.33%).
- The adjusted risk indicates that patients on BRAF inhibitors were over 7 times more likely to develop uveitis compared to those not treated with BRAF inhibitors, with even higher risks noted after matching for similar characteristics.
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol
October 2023
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
Background: Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated with these therapies has been reported in clinical trials, the real-world incidence is poorly defined, as are risk factors for its development.
Objectives: This study sought to characterize the incidence, time course, and risk factors for cancer therapy-related cardiac dysfunction (CTRCD) in patients with melanoma receiving BRAF and MEK inhibitors.
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.
Biomed Pharmacother
December 2023
Friedrich Loeffler - Institute of Medical Microbiology - Virology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany. Electronic address:
Primary and acquired therapy resistance is a major problem in patients with BRAF-mutant melanomas being treated with BRAF and MEK inhibitors (BRAFI, MEKi). Therefore, development of alternative therapy regimes is still required. In this regard, new drug combinations targeting different pathways to induce apoptosis could offer promising alternative approaches.
View Article and Find Full Text PDFBRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.
Can J Ophthalmol
December 2023
Blanton Eye Institute, Houston Methodist Hospital, Houston, TX; Weill Cornell Medicine, New York, NY; University of Texas Medical Branch, Galveston, TX; University of Texas MD Anderson Cancer Center, Houston, TX; Texas A&M School of Medicine, Bryan, TX; University of Iowa Hospitals and Clinics, Iowa City, IA. Electronic address:
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study.
J Clin Med
February 2023
Ophthalmology Department, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium.
In the last two decades, an increasing number of so-called molecular-targeted therapies have become available for the treatment of patients with advanced malignancies. These drugs have included inhibitors of proteins in the MAPK pathway, such as BRAF and MEK inhibitors, which are characterized by a distinct toxicity profile. The eye is particularly susceptible to adverse effects due to MEK inhibitors, and the term MEKAR (MEK-inhibitor-associated retinopathy) indicates the presence of subretinal fluid, mimicking central serous chorioretinopathy (CSC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!